# Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors

> **NCT05522582** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Yancheng First People's Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Methotrexate tablets
- **DRUG:** Anti-PD-1 monoclonal antibody
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT05522582
- **Lead sponsor:** Yancheng First People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-15
- **Primary completion:** 2023-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05522582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05522582, "Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05522582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*